Alis Biosciences then plans to list and offer big investors an easy way to spread their bets
Promising late-stage trial results lift US pharmaceutical group’s shares almost 15%
Latest executive order could shake up US pharma industry
Medical devices like group’s surgical robots have already been hit by the new US charges
US pharmaceutical group says patient in study experienced ‘potential drug-induced liver injury’
Move comes as government seeks to boost UK’s standing as drugs research leader
Fears that pharmaceuticals could yet be hit by tariffs have sent shares sharply lower
Pharma group builds out American supply chains as part of preparations for potential US tariffs
Under the scheme, drugmakers discount price of medicines sold in bulk to healthcare system
US consumers are likely to be hit by the price rises across sectors from aviation to autos
Deal is latest sign of the uptick in exits by private equity groups despite sluggish M&A activity
Acquisitions hold cure for pharma companies’ chronic patent cliff problem
AI unit is boosted by first external funding round led by OpenAI-backer Thrive Capital
Peter Marks says ‘truth and transparency are not desired’ by health secretary as measles outbreak spreads
European Medicines Agency says risks of potentially fatal side effects from donanemab outweigh benefits
US hedge fund gauged investor interest in German conglomerate’s consumer health business
Once researchers begin wondering whether their government might pull the rug from under them, the damage is done
The biotech group created a revolutionary technology but it never hit on a sustainable business
The health benefits could be so extreme that it upends the annuity market, hitting retirement incomes and insurers
London-listed drugmaker will establish research centre in Beijing
Ozempic might feature in US negotiations with Denmark over Greenland
Experts say there are regional disparities in medication access even as prescriptions rise
DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time
Industry lobby group calls for action from government ahead of summit in April
Academic institutions have frozen new hires and limited PhD places
